Event Type: The document is a regulatory filing containing the transcript of a post-results earnings conference call for Q1 FY27, hosted by DAM Capital Advisors.

Date and Time: The conference call was held on Tuesday, September 29, 2026. A specific start time was not mentioned in the transcript.

Purpose: The stated purpose of the call was to discuss the company's operational and financial performance for Q1 FY27, following its recent listing on the stock exchanges. It was the company's first-ever earnings call.

Earnings Announcement Timing: The call was held after the earnings announcement. The company's letter dated September 24, 2026, intimating the exchanges of the call, is referenced.

Management Participants: The following management representatives participated in the call:

  • Mr. Nishith Shah – Chairman and Whole-Time Director
  • Mr. Gaurang Parikh – Managing Director
  • Mr. Dhaval Parikh – Joint Managing Director
  • Mr. Pankil Dharia – Whole-Time Strategy and Business Development Director
  • Mr. Rahul Shroff – Chief Financial Officer

The moderator was Mr. Nitin Agarwal from DAM Capital Advisors.

Availability of Materials: The transcript of the call was filed with the stock exchanges on October 05, 2026, and was also uploaded to the company's investor relations website at https://www.prasolchem.com/investorrelations/.

UPSI Statement: The moderator's opening remarks included a standard caution that the call may contain forward-looking statements based on beliefs and opinions as of the call date, which are not guarantees of future performance. The company did not include a specific statement confirming that no Unpublished Price Sensitive Information (UPSI) would be shared.

Financial Highlights Discussed:

  • Q1 FY27 Revenue: Stood at INR 433.6 crores, up 35.7% YoY from INR 319.6 crores in Q1 FY26. Growth was driven by steady volumes, better product mix, and higher realizations.
  • Revenue Mix: Acetone-based specialty chemicals (~40%), Phosphorus-based specialty chemicals (~40%), Other specialty chemicals (~20%). Exports accounted for 27% of revenue.
  • Gross Margin: Was 37.9% for the quarter, compared to 30% in Q1 FY26. This included an estimated INR 25 crores positive impact from inventory gains due to rising petrochemical prices.
  • EBITDA: Was INR 90.3 crores, up 122.4% YoY from INR 40.6 crores. EBITDA margin was 20.8% vs. 12.7% in Q1 FY26. This included a INR 0.92 crores positive impact from foreign currency fluctuations.
  • Profit After Tax (PAT): Was INR 61 crores, up 151% YoY from INR 24.3 crores, with a PAT margin of 14.1%.
  • Balance Sheet (as of Mar 31, 2026): Net worth stood at INR 448.5 crores. Gross debt was INR 110.1 crores with a net debt-to-equity of 0.19x. The net working capital cycle was 50 days.
  • IPO Proceeds: The fresh issue raised INR 80 crores (gross). Net proceeds of INR 76.4 crores were utilized with INR 60 crores for debt repayment and INR 16.4 crores for general corporate purposes.

Guidance and Forward-Looking Statements:

  • For FY27, the company expects revenue of INR 1,550 to 1,650 crores and an EBITDA of INR 240 to 250 crores. This guidance explicitly excludes potential price fluctuations from geopolitical issues and forex gains/losses, such as the Q1 inventory gain.
  • The company aspires to scale the business to INR 2,800 to 3,000 crores in the next 5 years.
  • On a normalized basis, sustainable gross margins are seen in the range of 30% to 32%.

Strategic and Operational Updates:

  • Capacity: Combined installed capacity is 98,000 TPA across ISO-certified, zero-liquid-discharge plants in Khopoli (78,800 TPA) and Mahad (19,900 TPA). Mahad utilization improved from 13% in FY24 to 44% in FY26 and is now EBITDA positive.
  • Expansion (Phase 1): A capex of INR 250 to 300 crores is planned over the next two years for debottlenecking and expanding existing products. This is expected to generate INR 500 to 550 crores of incremental revenue at peak utilization. It will be funded through internal accruals and potentially some additional debt.
  • Expansion (Phase 2): A subsequent capex of INR 250 to 300 crores is envisioned for new R&D products with better margins; details are still in progress.
  • New Products: 13 new products were commercialized in the last 3 years across mining, agro, lubricants, and construction. Key near-term products include:
  • An antibacterial drug using a new proprietary technology, with mechanical completion expected by January 2027.
  • Lubricant additive capacity expansion via debottlenecking (50-70% increase) within 2-3 months.
  • Mining chemicals, which are in the early pipeline with approvals in progress.
  • R&D: 40 products are in the R&D pipeline, with a dedicated application testing lab for lubricants, construction, and mining chemicals being set up.
  • Land Bank: The company has a 20-acre surplus at Mahad and 10-12 acres at Khopoli for future expansion.

Additional Notes Section

  • The document is an enclosure to a formal letter sent to the National Stock Exchange (NSE) and BSE Limited, submitted pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015.
  • The transcript is explicitly marked as "E&OE" (Errors and Omissions Excepted) and notes that in case of discrepancy, the official audio recordings uploaded on the stock exchange on September 29, 2026, will prevail.
  • No new financial data was disclosed in this specific announcement document (the covering letter). All financial figures and strategic details summarized above were extracted from the enclosed transcript of the previously held conference call.